Alvogen today announced that its subsidiary, Alvogen Romania, has launched generic versions of three oncology products: exemestane, irinotecan and letrozole.
- Complements a fast growing product pipeline
- 13 product launchings in Romania in 2011
- Global pipeline of over 200 products
Parsippany, New Jersey, August 11, 2011 - Alvogen, the US-based generic pharmaceuticals company, today announced that its subsidiary, Alvogen Romania, has launched generic versions of three oncology products. Exemestane (Aromasin), Irinotecan (Campto) and Letrozole (Femara) will complement a fast growing product portfolio in Romania. The company expects to launch 13 generic products in Romania in 2011 and deliver strong revenue growth over 2010. Currently, Alvogen has over 200 products in development and registrations for global markets and expects a total of 100 product launches in 2011.
Exemestane is an oral aromatase inhibitor, a treatment for early breast cancer in postmenopausal women. It is the generic equivalent of Pfizer’s Aromasin, available in 25 mg tablets.
Irinotecan (Irinotecan hydrochloride trihydrate) is the generic equivalent of Pfizer’s Campto and is a cytostatic, a treatment for advanced colorectal cancer. The product is available in a 20 mg/ml amber tubular glass vial.
Letrozole is an oral non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery in postmenopausal women. It is the generic equivalent of Novartis’s Femara, available in a carton box containing 30 film-coated tablets.
All three products are fully compensated by Romania’s National Health Insurance Fund and available in the Alvogen Romania warehouse for immediate shipment to hospitals and pharmacies.